Henlius press release
Web2 okt. 2024 · Press Release. By: Ref: Henlius. Published: 10/02/2024. Shanghai, China, September 29 th, 2024 – Shanghai Henlius Biotech, Inc. (2696.HK) announced that the … Web16 mrt. 2024 · Search. Please enter a search term.
Henlius press release
Did you know?
Web20 apr. 2024 · The National Medical Products Administration (NMPA) of China has accepted Shanghai Henlius Biotech’s New Drug Application (NDA) for Hansizhuang (serplulimab) for use in combination with chemotherapy for the first-line treatment of extensive stage small cell lung cancer (ES-SCLC). Web22 mrt. 2024 · 22-03-2024 China’s Fosun Pharma’s biotech arm Henlius is preparing to get its PD1 antibody serplulimab into hospitals nationwide once it is approved in China, and supply its four approved biosimilars with enhanced manufacturing capacity, said Henlius chief executive Zhang Wenjie at a press meeting held in Shanghai on March 17.
WebPress Releases. PR Newswire. Henlius 2024 Annual Results: Significant Achievements in Commercialisation, Surged to RMB3.2 Billion in Revenues. Henlius (2696.HK) … Web11 apr. 2024 · 香港, Apr 11, 2024 - (ACN Newswire) - 億勝生物科技有限公司（「億勝生物」或「集團」，股份代碼：1061.HK）欣然宣佈，集團全資附屬子公司珠海億勝醫藥有限公司（「億勝醫藥」）與日本郡是株式會社（「郡是」）全資子公司郡是醫療器材（深圳）有限公司（「郡是深圳」）達成合作，就由郡是生產、郡 ...
WebHenlius 复宏汉霖 8,289 followers 14h We just released our annual results for 2024. In 2024, Henlius (HKEX: 2696) saw revenues climb 91.1% to RMB3.21 billion as a result of … Web7 apr. 2024 · The FDA has granted orphan drug designation to serplulimab (HLX10) for the treatment of patients with small cell lung cancer (SCLC), according to a press release …
Web11 sep. 2024 · China’s Henlius Biotech has pressed go on a $477 million initial public offering (IPO) on the Hong Kong stock exchange that will support its drive into in-house …
Web31 mrt. 2024 · SHANGHAI, March 31, 2024 /PRNewswire/ -- Henlius (2696.HK) announced its 2024 annual results. In 2024, Henlius' revenue reached about RMB3.2147 billion, … technisat digitradio up 1 - dab+Web23 mrt. 2024 · Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide … technisat digitradio up 1Web21 dec. 2024 · Shanghai Henlius received the China Food and Drug Administration ("CFDA") approval for clinical trials of the Product for the indication of breast cancer in July 2015. As of the date of this announcement, the Product for the indication of breast cancer has officially entered phase III trial. technisat digitradio car 2 dab+Web31 mrt. 2024 · Press Release Henlius 2024 Annual Results: Significant Achievements in Commercialisation, Surged to RMB3.2 Billion in Revenues Published: March 31, 2024 at … technisat digit s3 hd manualWeb16 mrt. 2024 · SHANGHAI, March 16, 2024 /PRNewswire/ -- Henlius (2696.HK) announced its annual results for the year ended December 31st, 2024, sharing the company's recent … technisat digitradio up 55Web31 mrt. 2024 · SHANGHAI, March 31, 2024 /PRNewswire/ -- Henlius (2696.HK) announced its 2024 annual results. In 2024, Henlius' revenue reached about RMB3.2147 billion, About technisat edelgrill m1500ts teppanyakiWeb18 aug. 2024 · As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innovative biopharmaceuticals to patients worldwide … technisat digitradio up 1 display